Production of [211At]-Astatinated Radiopharmaceuticals and Applications in Targeted α-Particle Therapy
- 1 February 2013
- journal article
- review article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 28 (1), 1-20
- https://doi.org/10.1089/cbr.2012.1292
Abstract
(211)At is a promising radionuclide for α-particle therapy of cancers. Its physical characteristics make this radionuclide particularly interesting to consider when bound to cancer-targeting biomolecules for the treatment of microscopic tumors. (211)At is produced by cyclotron irradiation of (209)Bi with α-particles accelerated at ~28 MeV and can be obtained in high radionuclidic purity after isolation from the target. Its chemistry resembles iodine, but there is also a tendency to behave as a metalloid. However, the chemical behavior of astatine has not yet been clearly established, primarily due to the lack of any stable isotopes of this element, which precludes the use of conventional analytical techniques for its characterization. There are also only a limited number of research centers that have been able to produce this element in sufficient amounts to carry out extensive investigations. Despite these difficulties, chemical reactions typically used with iodine can be performed, and a number of biomolecules of interest have been labeled with (211)At. However, most of these compounds exhibit unacceptable instability in vivo due to the weakness of the astatine-biomolecule bond. Nonetheless, several compounds have shown high potential for the treatment of cancers in vitro and in several animal models, thus providing a promising basis that has allowed initiation of the first two clinical studies.Keywords
This publication has 121 references indexed in Scilit:
- Reagents for Astatination of Biomolecules. 5. Evaluation of Hydrazone Linkers in 211At- and 125I-Labeled closo-Decaborate(2-) Conjugates of Fab′ as a Means of Decreasing Kidney RetentionBioconjugate Chemistry, 2011
- Towards translation of 212Pb as a clinical therapeutic; getting the lead in!Dalton Transactions, 2011
- Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissuesNuclear Medicine and Biology, 2010
- Reagents for Astatination of Biomolecules. 4. Comparison of Maleimido-closo-Decaborate(2-) and meta-[211At]Astatobenzoate Conjugates for Labeling anti-CD45 Antibodies with [211At]AstatineBioconjugate Chemistry, 2009
- Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of α-particle-emitting 211At-labeled trastuzumabNuclear Medicine and Biology, 2009
- Reagents for Astatination of Biomolecules. 3. Comparison of closo-Decaborate(2-) and closo-Dodecaborate(2-) Moieties as Reactive Groups for Labeling with Astatine-211Bioconjugate Chemistry, 2009
- Preparation of Rh[16aneS4-diol]211At and Ir[16aneS4-diol]211At Complexes as Potential Precursors for Astatine Radiopharmaceuticals. Part I: SynthesisBioconjugate Chemistry, 2008
- Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodiesNuclear Medicine and Biology, 2007
- Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1Proceedings of the National Academy of Sciences of the United States of America, 2007
- A kit method for the high level synthesis of [211At]MABGBioorganic & Medicinal Chemistry, 2007